Phibro Animal Health Corp (PAHC) was Reiterated by Guggenheim to “Buy” while Lowering the Price Target of the company shares to $ 34 from a previous price target of $38 . Guggenheim advised their investors in a research report released on Apr 11, 2016.
Many Wall Street Analysts have commented on Phibro Animal Health Corp. Phibro Animal Health Corp was Initiated by Credit Suisse to “Outperform” on Feb 4, 2016. Shares were Downgraded by Barclays on Jan 15, 2016 to ” Underweight” and Lowered the Price Target to $ 31 from a previous price target of $36 .
On the company’s financial health, Phibro Animal Health Corp reported $0.39 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Feb 9, 2016. Analyst had a consensus of $0.40. The company had revenue of $191.80 million for the quarter, compared to analysts expectations of $198.27 million. The company’s revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.35 EPS.
Phibro Animal Health Corp closed down -3.09 points or -11.49% at $23.8 with 6,72,548 shares getting traded on Monday. Post opening the session at $26.94, the shares hit an intraday low of $23.005 and an intraday high of $26.94 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Feb 23, 2016, Gerald K Carlson (Chief Operating Officer) sold 8,000 shares at $28.09 per share price. According to the SEC, on Feb 19, 2016, Jack Bendheim (President and CEO) sold 2,175 shares at $30.01 per share price. On Feb 3, 2016, Larry Lee Miller (President) sold 60,000 shares at $33.58 per share price, according to the Form-4 filing with the securities and exchange commission.
Phibro Animal Health Corporation is an animal health and mineral nutrition company. The Company is engaged in developing manufacturing and marketing products for a range of food animals including poultry swine beef and dairy cattle and aquaculture. The Company operates through three segments: Animal Health Mineral Nutrition and Performance Products. Its Animal Health segment develops manufactures and markets more than 550 product presentations including antibacterials nutritional specialty products and vaccines. Mineral Nutrition segment manufactures and markets more than 425 formulations and concentrations of trace minerals such as zinc manganese copper iron and other compounds with a focus on customers in North America. The Company’s Performance Products segment manufactures and markets specialty ingredients for use in the personal care automotive industrial chemical and chemical catalyst industries predominantly in the United States.